Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 167
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Psychiatry Clin Neurosci ; 76(8): 367-376, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35543406

ABSTRACT

AIM: To establish treatment response biomarkers that reflect the pathophysiology of depression, it is important to use an integrated set of features. This study aimed to determine the relationship between regional brain activity at rest and blood metabolites related to treatment response to escitalopram to identify the characteristics of depression that respond to treatment. METHODS: Blood metabolite levels and resting-state brain activity were measured in patients with moderate to severe depression (n = 65) before and after 6-8 weeks of treatment with escitalopram, and these were compared between Responders and Nonresponders to treatment. We then examined the relationship between blood metabolites and brain activity related to treatment responsiveness in patients and healthy controls (n = 36). RESULTS: Thirty-two patients (49.2%) showed a clinical response (>50% reduction in the Hamilton Rating Scale for Depression score) and were classified as Responders, and the remaining 33 patients were classified as Nonresponders. The pretreatment fractional amplitude of low-frequency fluctuation (fALFF) value of the left dorsolateral prefrontal cortex (DLPFC) and plasma kynurenine levels were lower in Responders, and the rate of increase of both after treatment was correlated with an improvement in symptoms. Moreover, the fALFF value of the left DLPFC was significantly correlated with plasma kynurenine levels in pretreatment patients with depression and healthy controls. CONCLUSION: Decreased resting-state regional activity of the left DLPFC and decreased plasma kynurenine levels may predict treatment response to escitalopram, suggesting that it may be involved in the pathophysiology of major depressive disorder in response to escitalopram treatment.


Subject(s)
Depressive Disorder, Major , Depressive Disorder, Major/therapy , Escitalopram , Humans , Kynurenine , Magnetic Resonance Imaging , Prefrontal Cortex/diagnostic imaging , Transcranial Magnetic Stimulation
2.
Psychiatry Clin Neurosci ; 76(1): 22-31, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34626144

ABSTRACT

AIM: Globally, evidence from short-term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long-term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective, especially for drugs that have not yet been studied. The Japan Useful Medication Program for Schizophrenia (JUMPs) is a large-scale, long-term naturalistic study to present pivotal 52-week data on the continuity of second-generation antipsychotics (SGA: aripiprazole, blonanserin, and paliperidone). METHODS: JUMPs was an open-label, three-arm, randomized, parallel-group, 52-week study. Enrolled patients had schizophrenia, were ≥20 years old, and required antipsychotic treatment or switched from previous therapy. The primary endpoint was treatment discontinuation rate over 52 weeks. Secondary outcomes included remission rate, social functioning, and quality-of-life scores [Personal and Social Performance Scale (PSP) and EuroQol-5 dimensions], and safety. RESULTS: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). The discontinuation rate (P = 0.9771) and remission rates (P > 0.05) over 52 weeks did not differ significantly between the three treatment groups. The discontinuation rates were 68.3%, 68.2%, and 65.5% in the aripiprazole, blonanserin, and paliperidone groups, respectively. Significant improvements (all P < 0.05) from baseline in PSP scores were observed at start of monotherapy, week 26, and week 52 in the overall cohort and blonanserin group and at week 26 in the aripiprazole group. The adverse event profile favored blonanserin. CONCLUSION: All three SGAs evaluated in this study showed similar treatment discontinuation rates in patients with chronic schizophrenia in Japan.


Subject(s)
Antipsychotic Agents/administration & dosage , Antipsychotic Agents/therapeutic use , Medication Adherence/statistics & numerical data , Remission Induction , Schizophrenia/drug therapy , Social Interaction/drug effects , Antipsychotic Agents/adverse effects , Aripiprazole , Female , Humans , Japan , Male , Middle Aged , Paliperidone Palmitate , Piperazines , Piperidines , Treatment Outcome
3.
Psychiatry Clin Neurosci ; 74(9): 466-471, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32445495

ABSTRACT

AIM: Sex differences in serum folate concentrations are well known, but no studies have investigated the association between serum folate levels and schizophrenia based on sex. With this study in a Japanese population, we examined the difference in serum folate levels between patients with schizophrenia and non-psychiatric controls stratified by sex. The relations among serum folate levels, plasma total homocysteine (tHcy), and serum vitamin B6 (pyridoxal) levels were also examined using data from our previous studies. METHODS: The serum folate concentrations of 482 patients diagnosed with schizophrenia and 1350 non-psychiatric control subjects were measured. We conducted an analysis of covariance to examine the differences in serum folate levels between the two groups based on sex. Spearman's rank correlation was used to evaluate the relations among folate, tHcy, and vitamin B6 levels. RESULTS: In the control group, serum folate concentrations were higher in women than in men. Lower levels of serum folate were observed in both male and female patients with schizophrenia. An inverse correlation between serum folate and plasma tHcy and a weak positive correlation between serum folate and vitamin B6 were observed in the combined cohort. CONCLUSION: Our findings suggest that: (i) a low serum folate level may be associated with schizophrenia regardless of sex; and (ii) folate administration may be beneficial for the treatment of schizophrenia. In schizophrenic patients with low serum folate levels, folate administration might result in improvements in high tHcy and an increase in low vitamin B6 levels.


Subject(s)
Folic Acid/blood , Homocysteine/blood , Schizophrenia/blood , Vitamin B 6/blood , Aged , Female , Humans , Japan , Male , Middle Aged , Sex Factors
4.
Int J Neuropsychopharmacol ; 21(7): 631-639, 2018 07 01.
Article in English | MEDLINE | ID: mdl-29529289

ABSTRACT

Background: An imbalance in the inflammatory tumor necrosis factor system, including soluble tumor necrosis factor receptor 2 (sTNFR2), may contribute to the pathophysiology of schizophrenia. Methods: We measured the plasma levels of sTNFR2 in 256 healthy controls and 250 patients with schizophrenia including antipsychotic drug-free patients and treatment-resistant patients. We also explored the possible association between plasma sTNFR2 levels and cognitive performance in healthy controls and patients with schizophrenia using the Wechsler Adult Intelligence Scale, Third Edition, the Wechsler Memory Scale-Revised, and the Rey Auditory Verbal Learning Test. An association between plasma sTNFR2 levels and hippocampal volume in controls and patients with schizophrenia was also investigated via MRI. Results: We found that the plasma levels of sTNFR2 were significantly higher in patients with schizophrenia, including both antipsychotic drug-free patients and treatment-resistant patients. We found a significant negative association between plasma sTNFR2 levels and cognitive performance in controls and patients with schizophrenia. Hippocampal volume was also negatively associated with plasma sTNFR2 levels in patients with schizophrenia. Conclusion: Together, these convergent data suggest a possible biological mechanism for schizophrenia, whereby increased sTNFR2 levels are associated with a smaller hippocampal volume and cognitive impairment.


Subject(s)
Cognitive Dysfunction/physiopathology , Hippocampus/pathology , Receptors, Tumor Necrosis Factor, Type II/blood , Schizophrenia/blood , Schizophrenia/pathology , Schizophrenia/physiopathology , Adult , Aged , Cognitive Dysfunction/etiology , Female , Hippocampus/diagnostic imaging , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Schizophrenia/complications
5.
J Psychiatry Neurosci ; 43(3): 194-200, 2018 05.
Article in English | MEDLINE | ID: mdl-29688875

ABSTRACT

BACKGROUND: Alterations in one-carbon metabolism have been associated with schizophrenia, and vitamin B6 is one of the key components in this pathway. METHODS: We first conducted a case-control study of serum pyridoxal levels and schizophrenia in a large Japanese cohort (n = 1276). Subsequently, we conducted a meta-analysis of association studies (n = 2125). Second, we investigated whether rs4654748, which was identified in a genome-wide association study as a vitamin B6-related single nucleotide polymorphism, was genetically implicated in patients with schizophrenia in the Japanese population (n = 10 689). Finally, we assessed the effect of serum pyridoxal levels on schizophrenia risk using a Mendelian randomization (MR) approach. RESULTS: Serum pyridoxal levels were significantly lower in patients with schizophrenia than in controls, not only in our cohort, but also in the pooled data set of the meta-analysis of association studies (standardized mean difference -0.48, 95% confidence interval [CI] -0.57 to -0.39, p = 9.8 × 10-24). We failed to find a significant association between rs4654748 and schizophrenia. Furthermore, an MR analysis failed to find a causal relationship between pyridoxal levels and schizophrenia risk (odds ratio 0.99, 95% CI 0.65-1.51, p = 0.96). LIMITATIONS: Food consumption and medications may have affected serum pyridoxal levels in our cross-sectional study. Sample size, number of instrumental variables and substantial heterogeneity among patients with schizophrenia are limitations of an MR analysis. CONCLUSION: We found decreased serum pyridoxal levels in patients with schizophrenia in this observational study. However, we failed to obtain data supporting a causal relationship between pyridoxal levels and schizophrenia risk using the MR approach.


Subject(s)
Genetic Predisposition to Disease/genetics , Pyridoxal/blood , Schizophrenia/blood , Schizophrenia/genetics , Case-Control Studies , Female , Humans , Male , Middle Aged , Neoplasm Proteins/genetics , Polymorphism, Single Nucleotide/genetics
6.
J Psychiatry Neurosci ; 43(2): 170053, 2018 Feb 02.
Article in English | MEDLINE | ID: mdl-29402374

ABSTRACT

BACKGROUND: Alterations in one-carbon metabolism have been associated with schizophrenia, and vitamin B6 is one of the key components in this pathway. METHODS: We first conducted a case-control study of serum pyridoxal levels and schizophrenia in a large Japanese cohort (n = 1276). Subsequently, we conducted a meta-analysis of association studies (n = 2125). Second, we investigated whether rs4654748, which was identified in a genome-wide association study as a vitamin B6-related single nucleotide polymorphism, was genetically implicated in patients with schizophrenia in the Japanese population (n = 10 689). Finally, we assessed the effect of serum pyridoxal levels on schizophrenia risk using a Mendelian randomization (MR) approach. RESULTS: Serum pyridoxal levels were significantly lower in patients with schizophrenia than in controls, not only in our cohort, but also in the pooled data set of the meta-analysis of association studies (standardized mean difference -0.48, 95% confidence interval [CI] -0.57 to -0.39, p = 9.8 × 10-24). We failed to find a significant association between rs4654748 and schizophrenia. Furthermore, an MR analysis failed to find a causal relationship between pyridoxal levels and schizophrenia risk (odds ratio 0.99, 95% CI 0.65-1.51, p = 0.96). LIMITATIONS: Food consumption and medications may have affected serum pyridoxal levels in our cross-sectional study. Sample size, number of instrumental variables and substantial heterogeneity among patients with schizophrenia are limitations of an MR analysis. CONCLUSION: We found decreased serum pyridoxal levels in patients with schizophrenia in this observational study. However, we failed to obtain data supporting a causal relationship between pyridoxal levels and schizophrenia risk using the MR approach.

7.
BMC Psychiatry ; 17(1): 249, 2017 07 12.
Article in English | MEDLINE | ID: mdl-28701225

ABSTRACT

BACKGROUND: It has been reported that drugs which promote the N-Methyl-D-aspartate-type glutamate receptor function by stimulating the glycine modulatory site in the receptor improve negative symptoms and cognitive dysfunction in schizophrenia patients being treated with antipsychotic drugs. METHODS: We performed a placebo-controlled double-blind crossover study involving 41 schizophrenia patients in which D-cycloserine 50 mg/day was added-on, and the influence of the onset age and association with white matter integrity on MR diffusion tensor imaging were investigated for the first time. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Brief Assessment of Cognition in Schizophrenia (BACS), and other scales. RESULTS: D-cycloserine did not improve positive or negative symptoms or cognitive dysfunction in schizophrenia. The investigation in consideration of the onset age suggests that D-cycloserine may aggravate negative symptoms of early-onset schizophrenia. The better treatment effect of D-cycloserine on BACS was observed when the white matter integrity of the sagittal stratum/ cingulum/fornix stria terminalis/genu of corpus callosum/external capsule was higher, and the better treatment effect on PANSS general psychopathology (PANSS-G) was observed when the white matter integrity of the splenium of corpus callosum was higher. In contrast, the better treatment effect of D-cycloserine on PANSS-G and SANS-IV were observed when the white matter integrity of the posterior thalamic radiation (left) was lower. CONCLUSION: It was suggested that response to D-cycloserine is influenced by the onset age and white matter integrity. TRIAL REGISTRATION: UMIN Clinical Trials Registry (number UMIN000000468 ). Registered 18 August 2006.


Subject(s)
Antipsychotic Agents/administration & dosage , Cycloserine/analogs & derivatives , Glycine Agents/administration & dosage , Schizophrenia/drug therapy , Schizophrenic Psychology , Adult , Age of Onset , Cross-Over Studies , Cycloserine/administration & dosage , Diffusion Tensor Imaging , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Schizophrenia/pathology , White Matter/diagnostic imaging , White Matter/pathology
8.
Psychiatry Clin Neurosci ; 71(5): 328-335, 2017 May.
Article in English | MEDLINE | ID: mdl-27973723

ABSTRACT

AIM: The purpose of this study was to elucidate determinants of quality of life (QOL) in anorexia nervosa (AN) patients. METHODS: Twenty-one female patients with AN participated in the study. QOL was assessed with the 36-Item Short Form Health Survey (SF-36), and cognitive function was evaluated using the Wisconsin Card Sorting Test Keio version, the Rey Complex Figure Test, and the Social Cognition Screening Questionnaire. Clinical symptoms were evaluated with the Beck Depression Inventory-II, the State-Trait Anxiety Inventory-Form JYZ (STAI-JYZ), and the Maudsley Obsessive Compulsive Inventory. RESULTS: The Difficulty Maintaining Set score of the Wisconsin Card Sorting Test Keio version was negatively correlated to the SF-36 Physical Component Summary. Scores of the Beck Depression Inventory-II and the STAI-JYZ State and Trait were negatively correlated to the SF-36 Mental Component Summary (MCS), and the Central Coherence Index 30-min Delayed Recall score of the Rey Complex Figure Test was positively correlated with the MCS. Stepwise regression analysis showed that the Difficulty Maintaining Set score was an independent predictor of the Physical Component Summary and scores for Central Coherence Index 30-min Delayed Recall and the STAI-JYZ Trait-predicted MCS. CONCLUSION: These results suggest that not only trait anxiety but also poor central coherence and impaired ability to maintain new rule worsen AN patients' QOL.


Subject(s)
Anorexia Nervosa/psychology , Cognition , Quality of Life/psychology , Adult , Anorexia Nervosa/complications , Anxiety/complications , Anxiety/psychology , Case-Control Studies , Female , Humans , Neuropsychological Tests , Personality Inventory , Psychiatric Status Rating Scales , Young Adult
9.
Int J Mol Sci ; 18(3)2017 Mar 14.
Article in English | MEDLINE | ID: mdl-28335437

ABSTRACT

Clozapine is an atypical antipsychotic, that is established as the treatment of choice for treatment-resistant schizophrenia (SCZ). To date, no study investigating comprehensive DNA methylation changes in SCZ patients treated with chronic clozapine has been reported. The purpose of the present study is to reveal the effects of clozapine on DNA methylation in treatment-resistant SCZ. We conducted a genome-wide DNA methylation profiling in peripheral leukocytes (485,764 CpG dinucleotides) from treatment-resistant SCZ patients treated with clozapine (n = 21) in a longitudinal study. Significant changes in DNA methylation were observed at 29,134 sites after one year of treatment with clozapine, and these genes were enriched for "cell substrate adhesion" and "cell matrix adhesion" gene ontology (GO) terms. Furthermore, DNA methylation changes in the CREBBP (CREB binding protein) gene were significantly correlated with the clinical improvements. Our findings provide insights into the action of clozapine in treatment-resistant SCZ.


Subject(s)
Antipsychotic Agents/pharmacology , Clozapine/pharmacology , DNA Methylation/drug effects , Schizophrenia/genetics , Adult , Antipsychotic Agents/therapeutic use , CREB-Binding Protein/genetics , Clozapine/therapeutic use , CpG Islands , Drug Resistance , Female , Humans , Leukocytes/metabolism , Male , Middle Aged , Schizophrenia/drug therapy
10.
J Neural Transm (Vienna) ; 123(6): 637-41, 2016 06.
Article in English | MEDLINE | ID: mdl-27130565

ABSTRACT

The pathological mechanisms of schizophrenia (SCZ) have not been clarified, but the microglia hypothesis has recently been discussed. We previously reported that the mRNA for a protein related to activation of microglia, triggering receptor expressed on myeloid cell 2 (TREM2), is expressed higher in peripheral leukocytes in SCZ than controls. In this study, we analyzed TREM2 mRNA expression in leukocytes from both SCZ and major depressive disorder (MDD) patients. We compared 50 SCZ patients and 42 MDD patients with age-matched controls. Levels of TREM2 mRNA in leukocytes were analyzed with quantitative real-time PCR method using TaqMan probe. TREM2 mRNA expression was significantly higher in leukocytes of SCZ subjects than controls, but the expression level was non-significantly different in MDD subjects. We observed a decrease in TREM2 mRNA expression in leukocytes from one SCZ patient after clozapine treatment. The expression did not change following ECT, but the expression level in this patient was still significantly higher than that in controls. We conclude that the high amount of TREM2 mRNA expression in leukocytes is specific to SCZ but not MDD and that changes in TREM2 mRNA expression may be a trait biomarker for SCZ.


Subject(s)
Depressive Disorder, Major/blood , Leukocytes/metabolism , Membrane Glycoproteins/metabolism , Receptors, Immunologic/metabolism , Schizophrenia/blood , Aged , Female , Humans , Male , Middle Aged , RNA, Messenger/metabolism
11.
Int J Eat Disord ; 49(4): 402-6, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26446402

ABSTRACT

OBJECTIVE: Refeeding in patients with anorexia nervosa (AN) is associated with a risk of refeeding syndrome, which is a disruption in metabolism with a variety of features including hypophosphatemia. We evaluated the risk factors for refeeding hypophosphatemia (RH) during nutritional replenishment in Japanese patients with AN. METHODS: We retrospectively examined clinical data for 99 female inpatients (mean age 30.9 ± 10.7 years; range, 9 - 56 years). RESULTS: RH (phosphate < 2.3 mg/dL) occurred within 4.8 ± 3.7 days of hospital admission and was still observed at 28 days after admission in 21 of the 99 cases (21.2%). Oral or intravenous phosphate was given to some patients to treat or prevent RH. Patients with RH had a significantly lower body mass index, were older, and had higher blood urea nitrogen than those without RH. Severe complications associated with RH were recorded in only one patient who showed convulsions and disturbed consciousness at Day 3 when her serum phosphate level was 1.6 mg/dL. CONCLUSIONS: The significant risk factors for RH that we identified were lower body mass index, older age, and higher blood urea nitrogen at admission. No significant difference in total energy intake was seen between the RH and no RH groups, suggesting that RH may not be entirely correlated with energy intake. Precisely predicting and preventing RH is difficult, even in patients with AN who are given phosphate for prophylaxis. Thus, serum phosphate levels should be monitored for more than 5 days after admission.


Subject(s)
Anorexia Nervosa/therapy , Hypophosphatemia/etiology , Refeeding Syndrome/complications , Adolescent , Adult , Anorexia Nervosa/epidemiology , Child , Energy Intake/physiology , Female , Hospitalization/statistics & numerical data , Humans , Hypophosphatemia/epidemiology , Japan/epidemiology , Middle Aged , Refeeding Syndrome/epidemiology , Retrospective Studies , Risk Factors , Young Adult
12.
Hum Psychopharmacol ; 31(3): 193-9, 2016 05.
Article in English | MEDLINE | ID: mdl-27005686

ABSTRACT

The serotonin transporter (5HTT) may be associated with the pathogenesis of major depressive disorder (MDD). The 5HTT-linked polymorphic region (5HTTLPR) genotype may determine how levels of 5HTT mRNA are influenced by promoter methylation. We examined the association of 5HTT gene methylation, which influences gene expression, and the 5HTTLPR genotype before antidepressant treatment and expression before and after treatment. The aims of this study were (1) to investigate the association between 5HTT methylation or expression in leukocytes and depression and (2) to investigate a possible effect of 5HTT methylation, expression, and genotype on clinical symptoms in MDD. The 5HTTLPR genotype was significantly associated with mean methylation levels in patients only (patients: r = 0.40, p = 0.035, controls: p = 0.96). The mean methylation level was significantly increased in patients compared with controls (patients: 5.30 ± 0.24, controls: 4.70 ± 0.19, unpaired t-test, p = 0.04). 5HTT expression using real-time PCR and Taqman probes was increased in unmedicated patients compared with controls and then decreased 8 weeks after antidepressant treatment. The mean 5HTT expression level was not associated with the 5HTTLPR genotype in patients or controls. Increased depressive symptoms were related to decreased levels of methylation. Copyright © 2016 John Wiley & Sons, Ltd.


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder, Major/genetics , Gene Expression Regulation , Serotonin Plasma Membrane Transport Proteins/genetics , Adult , Case-Control Studies , DNA Methylation , Depressive Disorder, Major/drug therapy , Female , Follow-Up Studies , Genotype , Humans , Male , Middle Aged , Polymorphism, Genetic , Promoter Regions, Genetic , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction
13.
Seishin Shinkeigaku Zasshi ; 118(9): 680-687, 2016.
Article in Japanese | MEDLINE | ID: mdl-30620860

ABSTRACT

In 2014, Japanese Ministry of Health, Labour and Welfare published the guideline on the policy of the psychiatric hospitals. We executed a survey to the members of "The Japanese Society of Psychiatry and Neurology" about the impression of this guideline, especially about "The functional differentiation of psychiatric hospital beds". Nine questions were notified on the home page of the society. 862 answers (5.3% of the members) were corrected by website from 1st to 30th of May in 2015. Attribution of the answers : doctors working at the psychiatric hospitals (70.9%), the psychiatric clinics (20%), the others (9.1%). The questions which more than 80% of the answers agreed were "The reduction of the psychiatric beds should be stepwise under the rule of check & balance in the improvement of the psychiatric community treatment", "Improve the function of the recovery phase treatment" and "The adequate treat- ment for the patients of the severe and chronic phases". The questions more than 55% of the answers agreed were "The reduction of the chronic phase beds for the improvement of the function of the acute phase beds". The questions which opposites exceeded (almost 47%) were "The assessment of the psychiatric symptoms in the patients of the chronic phase should be done by the third party" and "The facility for social skill treatment should be placed in the community". We could know the mind of the members about the revolution of the psychiatric.


Subject(s)
Bedding and Linens/statistics & numerical data , Hospitals, Psychiatric/statistics & numerical data , Mental Disorders , Humans , Surveys and Questionnaires
14.
BMC Med Genet ; 16: 54, 2015 Jul 26.
Article in English | MEDLINE | ID: mdl-26208850

ABSTRACT

BACKGROUND: The results of meta-analyses conducted by previous association studies between total homocysteine and schizophrenia suggest that an elevated total homocysteine level is a risk factor for schizophrenia. However, observational studies have potential limitations, such as confounding and reverse causation. In the present study, we evaluated a causal relationship between plasma total homocysteine and schizophrenia by conducting a Mendelian randomization analysis. METHODS: We used the MTHFR C677T polymorphism as an instrumental variable, which affects the plasma total homocysteine levels. To calculate the risk estimate for the association of this single nucleotide polymorphism (SNP) with schizophrenia, we conducted a meta-analysis of case-control studies that comprise a total of 11,042 patients with schizophrenia and 14,557 control subjects. We obtained an estimate for the association of this SNP with the plasma total homocysteine levels from a meta-analysis of genome-wide association studies comprising 44,147 individuals. RESULTS: By combining these two estimates, we demonstrated a significant effect of the plasma total homocysteine on schizophrenia risk, representing an OR of 2.15 (95 % CI = 1.39-3.32; p = 5.3 x 10(-4)) for schizophrenia per 1-SD increase in the natural log-transformed plasma total homocysteine levels. CONCLUSIONS: We provided evidence of a causal relationship between the plasma total homocysteine and schizophrenia, and this result will add insight into the pathology and treatment of schizophrenia.


Subject(s)
Homocysteine/blood , Mendelian Randomization Analysis , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Schizophrenia/blood , Schizophrenia/epidemiology , Schizophrenia/genetics , Case-Control Studies , Genetic Predisposition to Disease , Humans , Polymorphism, Single Nucleotide , Risk Factors
15.
J Neural Transm (Vienna) ; 122(5): 731-2, 2015 May.
Article in English | MEDLINE | ID: mdl-25115936

ABSTRACT

Abnormal hexanucleotide repeat expansion of C9ORF72 is known to cause neurodegenerative disorders such as frontotemporal dementia. Additionally, patients with psychotic symptoms are more likely to have abnormal hexanucleotide repeat expansion than are patients without them. We investigated the hexanucleotide repeat sizes of C9ORF72 in 466 Japanese schizophrenia patients. We found no abnormal hexanucleotide repeat expansion. In conclusion, C9ORF72 may not be responsible for schizophrenia susceptibility in the Japanese population.


Subject(s)
DNA Repeat Expansion , Genetic Predisposition to Disease , Proteins/genetics , Schizophrenia/genetics , Asian People/genetics , C9orf72 Protein , DNA Mutational Analysis , Female , Humans , Japan , Male , Middle Aged
16.
Hum Psychopharmacol ; 30(5): 372-6, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26010653

ABSTRACT

OBJECTIVE: Catechol-O-methyltransferase (COMT) is an enzyme that participates in the metabolic inactivation of dopamine and norepinephrine, and the Met allele of the COMT Val158Met polymorphism is associated with lower enzymatic activity. The purpose of the present study was to investigate whether this functional variant is associated with obsessive-compulsive disorder (OCD) and the clinical responses in OCD. METHODS: We first performed a case-control association study between the COMT Val158Met polymorphism and OCD (171 cases and 944 controls). Then, we examined the association between this polymorphism and the clinical responses in 91 of the OCD patients. RESULTS: Our study did not find a significant association between the Met allele and OCD risk or between the Met allele and clinical responses (p > 0.05). CONCLUSION: The present case-control/pharmacogenetic study did not provide clear evidence that the COMT Val158Met polymorphism is a predictor of OCD or of OCD patients' clinical responses.


Subject(s)
Antipsychotic Agents/pharmacology , Catechol O-Methyltransferase/genetics , Obsessive-Compulsive Disorder/drug therapy , Obsessive-Compulsive Disorder/genetics , Outcome Assessment, Health Care , Selective Serotonin Reuptake Inhibitors/pharmacology , Adult , Antipsychotic Agents/administration & dosage , Drug Synergism , Female , Humans , Japan , Male , Middle Aged , Polymorphism, Single Nucleotide , Selective Serotonin Reuptake Inhibitors/administration & dosage
17.
Psychiatry Clin Neurosci ; 69(3): 145-52, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25296773

ABSTRACT

AIM: The aim of this study is to examine the hemodynamic changes induced by the cognitive process of facial expression by using multi-channel near-infrared spectroscopy in healthy subjects with varying degrees of autism tendency. METHODS: Subjects were 38 volunteers, 20 men and 18 women. Autism tendency was measured by the Autism Spectrum Quotient. The hemodynamic changes in the prefrontal cortex were measured by 24-channel near-infrared spectroscopy system, while subjects were asked to judge their own emotional response to standardized pictures of eight kinds of facial expressions on a computer screen. RESULTS: There were significant negative correlations between Autism Spectrum Quotient scores and accuracy of fearful expression recognition as well as increases in the concentration of oxygenated hemoglobin in response to four kinds of emotional faces (fear, contempt, sadness and disgust). CONCLUSION: Our findings suggest that the greater tendency to autism that subjects have, the more difficulty they have in recognizing a fearful expression and the less hemodynamic change in the prefrontal cortex they show in response to negative facial expressions.


Subject(s)
Autistic Disorder/diagnosis , Autistic Disorder/physiopathology , Healthy Volunteers/psychology , Hemodynamics/physiology , Prefrontal Cortex/blood supply , Recognition, Psychology/physiology , Adult , Facial Expression , Female , Functional Neuroimaging , Humans , Male , Photic Stimulation , Psychiatric Status Rating Scales , Spectroscopy, Near-Infrared , Young Adult
18.
Acta Neuropsychiatr ; 27(2): 113-8, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25529988

ABSTRACT

OBJECTIVE: Severe depression may be a risk factor for diagnostic conversion into bipolar disorder (BD), and psychotic depression (PD) has been consistently associated with BD. The aims of the present study were to investigate the stability of the diagnosis of severe depression and the differences between PD and non-psychotic severe depression (non-PD), as well as to assess the effectiveness of electroconvulsive therapy (ECT). METHODS: Patients who were hospitalised for severe depression (diagnosed according to ICD-10) both with and without psychotic symptoms (n=89; mean age=55.6 years, SD=13.9) from 2001 to 2010 were retrospectively assessed. RESULTS: By the 75th month of follow-up assessments, 11(12.4%) patients had developed BD. Among these 11 converters, nine had developed BD within 1 year after admission. Only sub-threshold hypomanic symptoms were significantly related to developing BD. The number of depressive episodes and history of physical diseases were significantly increased in non-PD compared with PD patients, whereas ECT was significantly increased in PD compared with non-PD patients. There was a significant association between length of stay at the hospital and the number of days between admission and ECT. CONCLUSION: Sub-threshold hypomanic symptoms may represent a prodrome of BD or an indicator of an already manifest phenotype, especially in older patients, which suggests cautious use of antidepressants. In severe depression, non-PD may often occur secondary to physical diseases and patients may experience increased recurrences compared with PD patients, which may be a more 'primary' disorder and often requires ECT treatments. ECT is effective for severe depression regardless of the presence of any psychotic feature; the earlier ECT is introduced, the better the expected treatment outcome.


Subject(s)
Bipolar Disorder/complications , Depressive Disorder, Major/complications , Psychotic Disorders/complications , Adult , Aged , Antidepressive Agents/therapeutic use , Bipolar Disorder/epidemiology , Bipolar Disorder/therapy , Comorbidity , Depressive Disorder, Major/epidemiology , Depressive Disorder, Major/therapy , Diagnosis, Differential , Electroconvulsive Therapy/adverse effects , Electroconvulsive Therapy/methods , Female , Hospitalization , Humans , Japan/epidemiology , Male , Middle Aged , Psychotic Disorders/epidemiology , Psychotic Disorders/therapy , Retrospective Studies , Risk Factors
19.
Seishin Shinkeigaku Zasshi ; 117(12): 1004-10, 2015.
Article in Japanese | MEDLINE | ID: mdl-27044143

ABSTRACT

The essence of drug therapy is to avoid the unnecessary use of drugs. We must initially consider whether or not to use a drug. For a depressive state, drugs are not necessary for an understandable psychological reaction, and should be carefully prescribed for mild depression with minor impairment in social and occupational functioning. Antidepressants do not have non-specific mood improvement effects. They exert effects by correcting the neurochemical imbalance related to the pathological depression. When we use pharmacotherapy, monotherapy is the basis. Monotherapy allows us to estimate the effects and side-effects properly, and to check the results with clinical evidence. Although the benefits of drug therapy are certain, we must remember that the risks cannot be reduced to zero even with efforts to minimize them.


Subject(s)
Affect/drug effects , Antidepressive Agents/administration & dosage , Antidepressive Agents/therapeutic use , Depression/drug therapy , Depressive Disorder/drug therapy , Depressive Disorder/diagnosis , Drug Therapy, Combination , Humans , Treatment Outcome
20.
Hum Psychopharmacol ; 29(2): 190-8, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24590544

ABSTRACT

OBJECTIVES: To elucidate the molecular effects of lithium, we studied global gene expression changes induced by lithium in leukocytes from healthy subjects. METHODS: Eight healthy male subjects participated in this study. Lithium was prescribed for weeks to reach a therapeutic serum concentration. Leukocyte counts and serum lithium concentrations were determined at baseline (before medication), after 1 and 2 weeks of medication and at 2 weeks after stopping medication. Gene expression profiling was performed at each time point using Agilent G4112F Whole Human Genome arrays (The Agilent Technologies, Santa Clara, CA, USA). Expression of some candidate genes was also assessed by real-time polymerase chain reaction (PCR). RESULTS: Gene ontology analysis revealed that the cellular and immune responses to stimulus and stress indeed played a major role in the cellular response to lithium treatment. Pathway analysis revealed that the interleukin 6 pathway, the inhibitor of differentiation pathway, and the methane metabolism pathway were regulated by lithium. Using real-time PCR, we also confirmed that five candidate genes in these pathways were significantly changed, including suppressor of cytokine signaling 3 and myeloperoxidase. CONCLUSIONS: Our investigation suggests that the molecular action of lithium is mediated in part by its effects on the cellular and immune response to stimulus and stress followed by the interleukin 6, inhibitor of differentiation, and methane metabolism pathways.


Subject(s)
Antimanic Agents/pharmacology , Gene Expression/drug effects , Leukocytes/drug effects , Leukocytes/metabolism , Lithium Compounds/pharmacology , Antimanic Agents/blood , Gene Expression Profiling , Humans , Interleukin-6/genetics , Interleukin-6/metabolism , Leukocyte Count , Lithium Compounds/blood , Male , Methane/metabolism , Microarray Analysis , Peroxidase/genetics , Peroxidase/metabolism , Polymerase Chain Reaction , Signal Transduction/drug effects , Signal Transduction/genetics , Signal Transduction/physiology , Suppressor of Cytokine Signaling 3 Protein , Suppressor of Cytokine Signaling Proteins/genetics , Suppressor of Cytokine Signaling Proteins/metabolism , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL